VHL-Mediated Regulation of CHCHD4 and Mitochondrial Function.
View / Open Files
Authors
Briston, Thomas
Stephen, Jenna M
Thomas, Luke W
Esposito, Cinzia
Chung, Yuen-Li
Syafruddin, Saiful E
Turmaine, Mark
Maddalena, Lucas A
Greef, Basma
Szabadkai, Gyorgy
Maxwell, Patrick H
Publication Date
2018Journal Title
Front Oncol
ISSN
2234-943X
Publisher
Frontiers Media SA
Volume
8
Pages
388
Language
eng
Type
Article
Physical Medium
Electronic-eCollection
Metadata
Show full item recordCitation
Briston, T., Stephen, J. M., Thomas, L. W., Esposito, C., Chung, Y., Syafruddin, S. E., Turmaine, M., et al. (2018). VHL-Mediated Regulation of CHCHD4 and Mitochondrial Function.. Front Oncol, 8 388. https://doi.org/10.3389/fonc.2018.00388
Abstract
Dysregulated mitochondrial function is associated with the pathology of a wide range of diseases including renal disease and cancer. Thus, investigating regulators of mitochondrial function is of particular interest. Previous work has shown that the von Hippel-Lindau tumor suppressor protein (pVHL) regulates mitochondrial biogenesis and respiratory chain function. pVHL is best known as an E3-ubiquitin ligase for the α-subunit of the hypoxia inducible factor (HIF) family of dimeric transcription factors. In normoxia, pVHL recognizes and binds hydroxylated HIF-α (HIF-1α and HIF-2α), targeting it for ubiquitination and proteasomal degradation. In this way, HIF transcriptional activity is tightly controlled at the level of HIF-α protein stability. At least 80% of clear cell renal carcinomas exhibit inactivation of the VHL gene, which leads to HIF-α protein stabilization and constitutive HIF activation. Constitutive HIF activation in renal carcinoma drives tumor progression and metastasis. Reconstitution of wild-type VHL protein (pVHL) in pVHL-defective renal carcinoma cells not only suppresses HIF activation and tumor growth, but also enhances mitochondrial respiratory chain function via mechanisms that are not fully elucidated. Here, we show that pVHL regulates mitochondrial function when re-expressed in pVHL-defective 786O and RCC10 renal carcinoma cells distinct from its regulation of HIF-α. Expression of CHCHD4, a key component of the disulphide relay system (DRS) involved in mitochondrial protein import within the intermembrane space (IMS) was elevated by pVHL re-expression alongside enhanced expression of respiratory chain subunits of complex I (NDUFB10) and complex IV (mtCO-2 and COX IV). These changes correlated with increased oxygen consumption rate (OCR) and dynamic changes in glucose and glutamine metabolism. Knockdown of HIF-2α also led to increased OCR, and elevated expression of CHCHD4, NDUFB10, and COXIV in 786O cells. Expression of pVHL mutant proteins (R200W, N78S, D126N, and S183L) that constitutively stabilize HIF-α but differentially promote glycolytic metabolism, were also found to differentially promote the pVHL-mediated mitochondrial phenotype. Parallel changes in mitochondrial morphology and the mitochondrial network were observed. Our study reveals a new role for pVHL in regulating CHCHD4 and mitochondrial function in renal carcinoma cells.
Keywords
CHCHD4, bioenergetics, hypoxia inducible factor, metabolism, mitochondria, respiratory chain, von Hippel-Lindau protein (pVHL)
Sponsorship
TB was funded by a British Heart Foundation (BHF) (FS/09/051) and METOXIA FP7 (HEALTH454 F2-2009-222741) awards to MA. JMS was funded by a Medical Research Council (MRC) Doctoral Training and Sackler award (RG70550) to MA. LWT was funded by MRC grants (MR/K002201/1, MR/K002201/2) to MA. CE was funded by a Cancer Research UK (CRUK) award (C7358/A19442) to MA. YLC was supported by the CR-UK and EPSRC Cancer Imaging Centre in association with the MRC and Department of Health (England) grant C1060/A10334, and CRUK grant C1060/A16464. LAM was funded by a CRUK PhD Studentship (RG91141) award to MA. BG was funded by a CRUK Clinical Research Training Fellowship (RG85993) award to MA. SV and SES were funded by MRC grant: Medical Research Council (MC_UU_12022/7).
Funder references
Wellcome Trust (096956/Z/11/Z)
Medical Research Council (MR/K002201/2)
Cancer Research UK (19442)
Cancer Research UK (C20/A19489)
Medical Research Council (MC_UU_12022/7)
Identifiers
External DOI: https://doi.org/10.3389/fonc.2018.00388
This record's URL: https://www.repository.cam.ac.uk/handle/1810/285342
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk